Pediatric Clinical Trials
We’re aggressively pursuing ways to help our patients right now — not years from now. That focus puts City of Hope among the worldwide leaders in administering clinical trials.
In a given year, City of Hope conducts more than 500 clinical trials enrolling more than 6,200 patients. Many of today’s most effective cancer and disease therapies are based on the results of clinical trials that depend on volunteer patients.
Current pediatric clinical trials include:
IRB 13272: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
This phase 2 trial studies the side effects and the best dose of genetically modified T cells after lymphodepleting chemotherapy in treating patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm that has returned after a period of improvement or has not responded to previous treatment.
IRB 13474: SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
This is a nonrandomized, open-label, multicenter study. A cycle of therapy is five consecutive days every 21 days for six or more cycles. Stage 1 will consist of a brief run-in period in which patients with BPDCN (previously untreated and previously treated) and AML (persistent/recurrent and previously untreated) will be treated with SL-401 at 3 dose levels. During Stage 2, two cohorts of BPDCN and AML patients will be treated at the maximum tolerated dose or maximum tested dose in which multiple dose-limiting toxicities are not observed (identified in Stage 1).
IRB 14269: A Phase 1/2 Trial of 8-Chloro-adenosine in Relapsed or Refractory Acute Myeloid Leukemia
This phase 1/2 trial studies the side effects and best dose of 8-chloro-adenosine and how well it works in treating patients with acute myeloid leukemia that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory).
IRB 15123: A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
The purpose of this first-in-human phase 1 study is to determine if AMG 330 given as a continuous IV infusion is safe and tolerable in adult subjects that have relapsed/refractory acute myeloid leukemia, and to determine the maximum tolerated dose and/or a biologically active dose.
IRB 15367: Pilot study of Crenolanib Combined with High-dose Cytarabine and Mitoxantrone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with relapsed/refractory AML irrespective the FLT3 status.
IRB 16203: A Phase 1 Study of SGN-CD123A in patients with relapsed or refractory Acute Myeloid Leukemia (AML)
The study will examine the safety profile of SGN-CD123A. The study will test increasing doses of SGN-CD123A given every three weeks to patients.
IRB 13447: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
This phase 1 trial studies the side effects and best dose of cellular immunotherapy in treating patients with high-risk acute lymphoblastic leukemia. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.
IRB 16180: A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma (T-ALL/T-LBL).
IRB 19130: A Phase 1 Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express An IL13Rα2-Targeting, Hinge-Optimized, 4-1BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brain Tumors
This study tests the intraventricular delivery of IL13Rα2-targeted CAR T cells in children with refractory or recurrent brain tumors.